Drugs /

bi 754111

Back to Drugs List

Overview

NCI Definition [1]:
A monoclonal antibody directed against the inhibitory receptor lymphocyte activation gene 3 protein (LAG3; LAG-3), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration,miptenalimab binds to LAG3 expressed on tumor-infiltrating lymphocytes (TILs) and blocks its binding with major histocompatibility complex (MHC) class II molecules expressed on tumor cells. This activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which leads to a reduction in tumor growth. LAG3, a member of the immunoglobulin superfamily (IgSF), is expressed on various immune cells, and negatively regulates both proliferation and activation of T-cells. Its expression on TILs is associated with tumor-mediated immune suppression.

Clinical Trials

View Clinical Trials for bi 754111

Bi 754111 has been investigated in 3 clinical trials, of which 3 are open and 0 are closed. Of the trials investigating bi 754111, 2 are phase 1 (2 open) and 1 is phase 2 (1 open).

Deficient DNA Mismatch Repair (dMMR), MLH1 Deficient Expression, and MSH2 Deficient Expression are the most frequent biomarker inclusion criteria for bi 754111 clinical trials.

Malignant solid tumor, adenocarcinoma of the gastroesophageal junction, and colorectal carcinoma are the most common diseases being investigated in bi 754111 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Bi 754111
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating bi 754111 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
miptenalimab, anti-lymphocyte activation gene 3 protein monoclonal antibody bi 754111, bi754111, bi-754111, anti-lag3 monoclonal antibody bi 754111
Drug Target(s) [2]:
LAG3
NCIT ID [1]:
C150403

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.